Patents by Inventor Jinhua Xiang

Jinhua Xiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein
    Patent number: 10034936
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 31, 2018
    Assignees: The University of Iowa Research Foundation, The United States of America as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent
    Patent number: 9611301
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 4, 2017
    Assignees: The University of Iowa Research Foundation, The United States of America as Represented by The Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Nirjal Bhattarai, Jinhua Xiang, James H. McLinden
  • VIRAL PROTEINS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
    Publication number: 20160067331
    Abstract: The invention provides compositions and methods involving viral envelope polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations.
    Type: Application
    Filed: March 14, 2014
    Publication date: March 10, 2016
    Inventors: Jack T. STAPLETON, Nirjal BHATTARAI, Jinhua XIANG, James H. MCLINDEN
  • GB VIRUS C (HEPATITIS G VIRUS) E2 GLYCOPROTEIN AS AN IMMUNOMODULATORY AGENT
    Publication number: 20150071955
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 12, 2015
    Applicant: THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Jack T. Stapleton, Nirjal Bhattarai, Jinhua Xiang, James H. McLinden
  • GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV
    Publication number: 20140348866
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Application
    Filed: August 15, 2014
    Publication date: November 27, 2014
    Applicants: THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT
    Inventors: Jack T. STAPLETON, Jinhua XIANG, Donna KLINZMAN, James H. McLINDEN
  • Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies
    Patent number: 8858946
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: October 14, 2014
    Assignees: The University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Flavivirus NS5A proteins for the treatment of HIV
    Patent number: 8268778
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: September 18, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: James McLinden, Jinhua Xiang, Jack T. Stapleton
  • Flavivirus NS5A proteins for the treatment of HIV
    Patent number: 7951531
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: May 31, 2011
    Assignee: University of Iowa Research Foundation
    Inventors: Jack T. Stapleton, Jinhua Xiang, Qing Chang, James McLinden
  • Flavivirus NS5A Proteins For the Treatment of HIV
    Publication number: 20100143454
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.
    Type: Application
    Filed: March 20, 2008
    Publication date: June 10, 2010
    Inventors: James McLinden, Jinhua Xiang, Jack T. Stapleton
  • GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV
    Publication number: 20090010932
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Application
    Filed: July 24, 2008
    Publication date: January 8, 2009
    Inventors: JACK T. STAPLETON, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • GB virus C and methods of treating viral infections
    Patent number: 7291723
    Abstract: The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: November 6, 2007
    Assignee: University of Iowa Research Foundation
    Inventors: Jack T. Stapleton, Jinhua Xiang, Sarah George
  • Flavivirus NS5A proteins for the treatment of HIV
    Publication number: 20070036825
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.
    Type: Application
    Filed: February 1, 2006
    Publication date: February 15, 2007
    Inventors: Jack Stapleton, Jinhua Xiang, Qing Chang, James McLinden
  • GB virus C and methods of treating viral infections
    Publication number: 20050119472
    Abstract: The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences.
    Type: Application
    Filed: October 24, 2003
    Publication date: June 2, 2005
    Inventors: Jack Stapleton, Jinhua Xiang, Sarah George
  • GB virus C (hepatitis G virus) for the treatment of HIV
    Publication number: 20050118181
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Application
    Filed: June 4, 2004
    Publication date: June 2, 2005
    Inventors: Jack Stapleton, Jinhua Xiang, Donna Klinzman, James McLinden
  • Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4 positive T cells
    Patent number: 6870043
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a recently described flavivirus that frequently leads to chronic viremia in humans. Although associated with acute post-transfusion hepatitis, it is not clear if GBV-C is pathogenic for humans. A full-length cDNA was constructed from the plasma of a person with chronic GBV-C viremia. Peripheral blood mononuclear cells (PBMCs) transfected with full-length RNA transcripts from this GBV-C clone resulted in viral replication, demonstrating an isolated infectious GBV-C nucleic acid molecule. In addition to composition involving an isolated infectious GBV-C nucleic acid molecule, the present invention concerns methods of inhibiting and treating HIV infections.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: March 22, 2005
    Assignee: The University of Iowa Research Foundation
    Inventors: Jinhua Xiang, Sabina Wünschmann, Warren Schmidt, Jack Stapleton
  • Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4 positive T cells and methods of treating HIV
    Publication number: 20030170870
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a recently described flavivirus that frequently leads to chronic viremia in humans. Although associated with acute post-transfusion hepatitis, it is not clear if GBV-C is pathogenic for humans. A full-length cDNA was constructed from the plasma of a person with chronic GBV-C viremia. Peripheral blood mononuclear cells (PBMCs) transfected with full-length RNA transcripts from this GBV-C clone resulted in viral replication, demonstrating an isolated infectious GBV-C nucleic acid molecule. In addition to composition involving an isolated infectious GBV-C nucleic acid molecule, the present invention concerns methods of inhibiting and treating HIV infections.
    Type: Application
    Filed: April 5, 2001
    Publication date: September 11, 2003
    Inventors: Jinhua Xiang, Sabina Wunschmann, Warren Schmidt, Jack Stapleton